Hosted on MSN1mon
Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils DividendRegeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo. The company also announced a dividend for the first time.
Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...
Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...
LIBTAYO (cemiplimab-rwlc) is a prescription medicine used to treat adults with NSCLC. LIBTAYO may be used alone as a first treatment option when your lung cancer has not spread outside your chest ...
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment ...
The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...
The potential to challenge incumbents Keytruda and Libtayo in the cSCC space is an exciting opportunity. The Checkpoint deal comes with a CVR related to approval of Unloxcyt in Europe, which may ...
Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on the National Health Service. This approval is for second-line monotherapy ...
Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial - - Data presented at AACR 2023 supports ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results